Literature DB >> 3664282

Sprouting of striatal serotonin nerve terminals following selective lesions of nigro-striatal dopamine neurons in neonatal rat.

J Luthman1, B Bolioli, T Tsutsumi, A Verhofstad, G Jonsson.   

Abstract

The effects of neonatal intracisternal 6-hydroxydopamine (6-OHDA; 50 micrograms) treatment on striatal serotonin (5-HT) nerve terminals in rat have been characterized using histo- and neurochemical methods. The 6-OHDA lesion caused a 60% reduction of striatal dopamine (DA) concentration when analyzed in the adult stage, while 5-HT levels were increased by about 40% and 3H-5-HT uptake in vitro was increased by about 60%. Using computerized image analysis, a marked increase in 5-HT-like immunoreactive terminal density was found in both rostral (+200%) and caudal (+50%) striatum. Pretreatment with the DA uptake blocker amfolenic acid completely counteracted the 6-OHDA-induced alterations in both DA and 5-HT neurons in the striatum, while pretreatment with the noradrenaline uptake blocker desipramine had no significant effects. Regional analysis of 5-HT levels in the CNS after neonatal 6-OHDA treatment or the combined desipramine + 6-OHDA treatment showed no significant effect in any of the brain areas analyzed, apart from the observed 5-HT increase in striatum. It was furthermore observed that the striatal 5-hydroxyindoleacetic acid (5-HIAA)/5-HT ratio was decreased, while the 3,4-dihydroxyphenylacetic acid (DOPAC)/DA ratio was increased following the 6-OHDA lesion, indicating compensatory mechanisms in turnover of transmitters. These alterations were completely reversed after pretreatment with amfolenic acid. The present results support the view that the 5-HT hyperinnervation following neonatal 6-OHDA treatment is a collateral sprouting response induced by lesioning of the striatal DA neurons.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3664282     DOI: 10.1016/0361-9230(87)90092-x

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  25 in total

1.  In vivo studies of the SERT-selective [18F]FPBM and VMAT2-selective [18F]AV-133 radiotracers in a rat model of Parkinson's disease.

Authors:  Julie L Wang; Shunichi Oya; Ajit K Parhi; Brian P Lieberman; Karl Ploessl; Catherine Hou; Hank F Kung
Journal:  Nucl Med Biol       Date:  2010-05       Impact factor: 2.408

2.  Neuronal Entropy-Rate Feature of Entopeduncular Nucleus in Rat Model of Parkinson's Disease.

Authors:  Olivier Darbin; Xingxing Jin; Christof Von Wrangel; Kerstin Schwabe; Atsushi Nambu; Dean K Naritoku; Joachim K Krauss; Mesbah Alam
Journal:  Int J Neural Syst       Date:  2015-10-06       Impact factor: 5.866

Review 3.  Neurobehavioral changes arising from early life dopamine signaling perturbations.

Authors:  Lorena B Areal; Randy D Blakely
Journal:  Neurochem Int       Date:  2020-04-20       Impact factor: 3.921

4.  In vivo electrochemical measurements of serotonin clearance in rat striatum: effects of neonatal 6-hydroxydopamine-induced serotonin hyperinnervation and serotonin uptake inhibitors.

Authors:  J Luthman; M N Friedemann; B J Hoffer; G A Gerhardt
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

Review 5.  Pharmacological models of ADHD.

Authors:  R M Kostrzewa; J P Kostrzewa; R A Kostrzewa; P Nowak; R Brus
Journal:  J Neural Transm (Vienna)       Date:  2007-11-12       Impact factor: 3.575

Review 6.  Dopamine receptor supersensitivity: development, mechanisms, presentation, and clinical applicability.

Authors:  Richard M Kostrzewa; John P Kostrzewa; Russell W Brown; Przemyslaw Nowak; Ryszard Brus
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

7.  Dopamine receptor supersensitivity: an outcome and index of neurotoxicity.

Authors:  Richard M Kostrzewa; John P Kostrzewa; Ryszard Brus
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

8.  Unilateral neonatal intracerebroventricular 6-hydroxydopamine administration in rats: I. Effects on spontaneous and drug-induced rotational behaviour and on postmortem monoamine levels.

Authors:  J Luthman; M Herrera-Marschitz; E Lindqvist
Journal:  Psychopharmacology (Berl)       Date:  1994-12       Impact factor: 4.530

9.  Dopamine receptor agonists regulate levels of the serotonin 5-HT2A receptor and its mRNA in a subpopulation of rat striatal neurons.

Authors:  N Laprade; F Radja; T A Reader; J J Soghomonian
Journal:  J Neurosci       Date:  1996-06-01       Impact factor: 6.167

Review 10.  Mouse models of hypoxanthine phosphoribosyltransferase deficiency.

Authors:  D J Williamson; M L Hooper; D W Melton
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.